The treatment landscape of CLL has changed significantly in recent years with the advent of targeted therapies such as B-cell lymphoma 2 (BCL2) and Bruton’s tyrosine kinase (BTK) inhibitors [1, 2]. This evidence concerns the gene BTK and B-cell chronic lymphocytic leukemia.